BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 33668876)

  • 41. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
    Kim A; Seong KM; Kang HJ; Park S; Lee SS
    Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Successful treatment of second-time CAR-T 19 therapy after failure of first-time CAR-T 19 and ibrutinib therapy in relapsed mantle cell lymphoma.
    Mu J; Liu M; Wang J; Meng J; Zhang R; Jiang Y; Deng Q
    Adv Clin Exp Med; 2022 Mar; 31(3):327-335. PubMed ID: 35148570
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
    Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
    Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.
    Li CJ; Jiang C; Liu Y; Bell T; Ma W; Ye Y; Huang S; Guo H; Zhang H; Wang L; Wang J; Nomie K; Zhang L; Wang M
    Mol Cancer Ther; 2019 Feb; 18(2):267-277. PubMed ID: 30413649
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Does Ibrutinib impact outcomes of viral infection by SARS-CoV-2 in mantle cell lymphoma patients?
    Alsuliman T; Faict S; Malard F; Genthon A; Brissot E; Van de Wyngaert Z; Ikhlef S; Banet A; Lapusan S; Sestili S; Corre E; M'hammedi-Bouzina F; Schaeffer L; Legrand O; Dulery R; Mohty M; Marjanovic Z
    Curr Res Transl Med; 2021 Jan; 69(1):103273. PubMed ID: 33460953
    [No Abstract]   [Full Text] [Related]  

  • 46. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
    Jain P; Kanagal-Shamanna R; Zhang S; Ahmed M; Ghorab A; Zhang L; Ok CY; Li S; Hagemeister F; Zeng D; Gong T; Chen W; Badillo M; Nomie K; Fayad L; Medeiros LJ; Neelapu S; Fowler N; Romaguera J; Champlin R; Wang L; Wang ML
    Br J Haematol; 2018 Nov; 183(4):578-587. PubMed ID: 30175400
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CD52 and OXPHOS-potential targets in ibrutinib-treated mantle cell lymphoma.
    Fuhr V; Heidenreich S; Srivastava M; Riedel A; Düll J; Gerhard-Hartmann E; Rosenwald A; Rauert-Wunderlich H
    Cell Death Discov; 2022 Dec; 8(1):505. PubMed ID: 36587029
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Zanubrutinib: a new BTK inhibitor for treatment of relapsed/refractory mantle cell lymphoma.
    Weaver AN; Jimeno A
    Drugs Today (Barc); 2020 Aug; 56(8):531-539. PubMed ID: 33025948
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ibrutinib for mantle cell lymphoma.
    Tucker DL; Rule SA
    Future Oncol; 2016 Feb; 12(4):477-91. PubMed ID: 26759179
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.
    Hagner PR; Chiu H; Ortiz M; Apollonio B; Wang M; Couto S; Waldman MF; Flynt E; Ramsay AG; Trotter M; Gandhi AK; Chopra R; Thakurta A
    Br J Haematol; 2017 Nov; 179(3):399-409. PubMed ID: 28771673
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma.
    Zhang S; Jiang VC; Han G; Hao D; Lian J; Liu Y; Zhang R; McIntosh J; Wang R; Dang M; Dai E; Wang Y; Santos D; Badillo M; Leeming A; Chen Z; Hartig K; Bigcal J; Zhou J; Kanagal-Shamanna R; Ok CY; Lee H; Steiner RE; Zhang J; Song X; Nair R; Ahmed S; Rodriquez A; Thirumurthi S; Jain P; Wagner-Bartak N; Hill H; Nomie K; Flowers C; Futreal A; Wang L; Wang M
    Nat Commun; 2021 May; 12(1):2877. PubMed ID: 34001881
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
    Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
    Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SHINE a light: frontline ibrutinib for MCL.
    Killock D
    Nat Rev Clin Oncol; 2022 Aug; 19(8):494. PubMed ID: 35750854
    [No Abstract]   [Full Text] [Related]  

  • 54. New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
    Rule S; Chen RW
    Expert Rev Hematol; 2018 Sep; 11(9):749-756. PubMed ID: 30052472
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Successful Long-Term Ibrutinib Treatment in a Hemodialysis Patient With Leukemic Nonnodal Mantle Cell Lymphoma.
    Yasuda H; Tsukune Y; Inano T; Mori Y; Ota Y; Komatsu N
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e176-e178. PubMed ID: 33127325
    [No Abstract]   [Full Text] [Related]  

  • 56. Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.
    Freeman CL; Pararajalingam P; Jin L; Balasubramanian S; Jiang A; Xu W; Grau M; Zapukhlyak M; Boyle M; Hodkinson B; Schaffer M; Enny C; Deshpande S; Sun S; Vermeulen J; Morin RD; Scott DW; Lenz G
    Leukemia; 2022 Oct; 36(10):2479-2487. PubMed ID: 35963941
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
    Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
    Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
    Bond DA; Alinari L; Maddocks K
    Clin Adv Hematol Oncol; 2019 Apr; 17(4):223-233. PubMed ID: 31188814
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro.
    Liu M; Wang X; Li Z; Zhang R; Mu J; Jiang Y; Deng Q; Sun L
    Cancer Sci; 2020 Nov; 111(11):4051-4060. PubMed ID: 32876369
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
    Molica S; Gianfelici V; Levato L
    Expert Opin Emerg Drugs; 2020 Mar; 25(1):25-35. PubMed ID: 31996046
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.